DHA-conjugated Phosphatidylserine and Autism: Scientific Evidence

DHA-conjugated phosphatidylserine (PS-DHA) is sometimes used as a nutritional supplement to support cognitive function and neurodevelopmental health. The rationale for its use in autism spectrum disorder (ASD) is primarily based on the roles of both docosahexaenoic acid (DHA), an omega-3 fatty acid crucial for brain function, and phosphatidylserine, a phospholipid involved in neuronal membrane structure and signaling. Some small studies and pilot trials have explored the benefits of omega-3 fatty acids and PS in children with ASD, with mixed results.

A few randomized controlled trials have examined omega-3 supplementation in ASD, with some reporting minor improvements in hyperactivity or social skills, but most found no statistically significant benefit in core autism symptoms. Research specifically on PS-DHA in ASD is limited, though one pilot study (Hirayama et al., 2014) suggested potential behavioral improvements in children with ASD, but this study was small and open-label, limiting the strength of its conclusions.

Currently, there is insufficient high-quality evidence to robustly support the use of DHA-conjugated phosphatidylserine for autism. The theoretical basis is plausible, and preliminary research is ongoing, but scientific validation remains limited. Most reviews and guidelines do not recommend PS-DHA as a standard or proven intervention for ASD.